ClinicalTrials.gg
CompletedNCT04169373SELECT-AXIS 2Updated Feb 24, 2026Results posted

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

A Phase 3 interventional study of Upadacitinib and Placebo in Spondyloarthritis, sponsored by AbbVie. Completed at 212 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Primary conditionAxial SpondyloarthritisRegistry: SpondylarthritisReclassifiedWhy we changed it
Registry
Spondylarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Axial Spondyloarthritis
Why
  1. The study's title name Axial Spondyloarthritis, a narrower term within Spondylarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
734
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Enrollment
3rd of 31
734 · median 200
Started
2019
with 3 others
Phase 3
13 of 34
none open now
Registered
21st of 34
by date
Lead sponsor
1 of 34
AbbVie

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2019, is one of 13 in phase 3, and was the 21st registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.

The main objectives of this protocol are:

  • To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2).
  • To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2).
  • To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2).
  • To evaluate the maintenance of disease control after withdrawal of upadacitinib.
Read the detailed description

Study 1 (bDMARD-IR AS) is comprised of a 14-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 90-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day Follow-Up Visit (F/U Visit).

Study 2 (nr-axSpA) is comprised of a 52-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 52-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day F/U Visit.

In the Double-Blind Period for both studies, participants are randomized in a 1:1 ratio to receive either upadacitinib or placebo once daily (QD).

Participants in the placebo group switch to upadacitinib 15 mg QD at Week 14 in the Open-Label Extension Period for Study 1 (bDMARD-IR AS) and Week 52 in the Open-Label Extension Period for Study 2 (nr-axSpA).

Participants in remission at Week 104 have the option to enroll in a remission-withdrawal period.

Study M19-944 protocol uses a common screening platform for determining eligibility into Study 1 and Study 2. Each study has its own objectives, hypothesis testing, randomization, data collection, and adequate power for primary and secondary endpoints. Analysis and reporting are conducted separately and independently for each study.

03

Conditions studied

  • Spondyloarthritis

Browse trials for

Keywords

  • Upadacitinib
  • Axial Spondyloarthritis (axSpA)
  • Spondyloarthritis
  • Ankylosing Spondylitis (AS)
04

In context

Axial Spondyloarthritis Reclassified

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

This study's enrollment of 734 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.

Browse Axial Spondyloarthritis studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Axial Spondyloarthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spondylarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study 1:

    • Must have a clinical diagnosis of ankylosing spondylitis (AS) and meet the modified New York Criteria for AS,
    • Must not have total spinal ankylosis
    • Must have been previously exposed to 1 or 2 bDMARDs (at least 1 tumor necrosis factor [TNF] inhibitor or 1 interleukin [IL]-17 inhibitor [IL-17i]), and must have discontinued the bDMARD therapy due to either lack of efficacy (after at least 12 weeks of treatment with a bDMARD at an adequate dose) or intolerance (irrespective of treatment duration). Prior exposure to two bDMARDs was allowed for no more than 30% of patients; among patients with prior exposure to two bDMARDs, a lack of efficacy to one bDMARD and intolerance to another was permitted, but a patient could not have a lack of efficacy to two bDMARDs
  • Study 2:

    • Must have a clinical diagnosis of nr-axSpA fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA but not meeting the radiologic criterion of the modified New York criteria for AS
    • Must have objective signs of active inflammation consistent with axSpA on magnetic resonance imaging (MRI) of sacroiliac (SI) joints or based on high sensitivity C-reactive protein (hsCRP) > the (ULN).
    • Prior treatment with at most one bDMARD (either TNF inhibitor or IL-17i) is allowed for at least 20% but no more than 35% of enrolled patients who had to discontinue the prior bDMARD due to either lack of efficacy (after ≥ 12 weeks at an adequate dose) or intolerance (regardless of treatment duration).
  • Must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at the Screening and Baseline Visits.
  • Must have a Total Back Pain score ≥ 4 based on a 0 - 10 numerical rating scale at the Screening and Baseline Visits.
  • Has had an inadequate response to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or has an intolerance to or for NSAIDs as defined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Must not have been exposed to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib [Rinvoq®], tofacitinib [Xeljanz®], baricitinib [Olumiant®], filgotinib, ruxolitinib [Jakafi®], abrocitinib [PF-04965842], and peficitinib [Smyraf®]).
  • Prior bDMARD therapy must be washed out.
  • Participant must not have a history of an allergic reaction or significant sensitivity to constituents of the study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
734 participants (actual)

Study arms

  • Experimental
    Study 1: Upadacitinib 15 mg

    Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).

    Drug: Upadacitinib

  • Placebo comparator
    Study 1: Placebo

    Participants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Study 2: Upadacitinib 15 mg

    Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).

    Drug: Upadacitinib

  • Placebo comparator
    Study 2: Placebo

    Participants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).

    Drug: Upadacitinib · Drug: Placebo

Interventions

  • Upadacitinib tablet administered orally

    Also known as: ABT-494, RINVOQ

  • DrugPlacebo

    Placebo for upadacitinib tablet administered orally

07

What researchers measure

Primary outcomes

  1. Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 14

  2. Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 14

Secondary outcomes

  1. Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.

    Time frame: Baseline and Week 14

  2. Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14

    In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  3. Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

    Time frame: Baseline and Week 14

  4. Study 1: Percentage of Participants With an ASAS20 Response at Week 14

    ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 14

  5. Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

    Time frame: Week 14

  6. Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

    Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

    Time frame: Baseline and Week 14

  7. Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

    Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

    Time frame: Baseline and Week 14

  8. Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

    Time frame: Week 14

  9. Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14

    The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

    Time frame: Baseline and Week 14

  10. Study 1: Percentage of Participants With ASAS Partial Remission at Week 14

    ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Week 14

  11. Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14

    The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

    Time frame: Baseline and Week 14

  12. Study 1: Change From Baseline in ASAS Health Index at Week 14

    The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  13. Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14

    The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  14. Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14

    The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  15. Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14

    In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  16. Study 2: Change From Baseline in ASDAS at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.

    Time frame: Baseline and Week 14

  17. Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14

    In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  18. Study 2: Percentage of Participants With BASDAI 50 Response at Week 14

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

    Time frame: Baseline and Week 14

  19. Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

    Time frame: Week 14

  20. Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

    Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

    Time frame: Baseline and Week 14

  21. Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

    Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

    Time frame: Baseline and Week 14

  22. Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

    Time frame: Week 14

  23. Study 2: Percentage of Participants With ASAS Partial Remission at Week 14

    ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Week 14

  24. Study 2: Change From Baseline in BASFI at Week 14

    The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

    Time frame: Baseline and Week 14

  25. Study 2: Change From Baseline in ASQoL at Week 14

    The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

    Time frame: Baseline and Week 14

  26. Study 2: Change From Baseline in ASAS Health Index at Week 14

    The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  27. Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14

    ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 14

  28. Study 2: Change From Baseline in BASMI(Lin) at Week 14

    The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  29. Study 2: Change From Baseline in MASES at Week 14

    The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  30. Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52

    ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Week 52

  31. Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14

    In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 14

  32. Study 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52

    Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.

    Time frame: Week 24, Week 32, Week 40, and Week 52

  33. Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.

    Time frame: Baseline and Week 52

  34. Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

    Time frame: Week 52

  35. Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

    Time frame: Week 52

08

Results

Posted Sep 21, 2022

Participant flow

This master protocol consists of 2 independent studies with a common screening platform for adults with active axial spondyloarthritis (axSpA). Study 1 enrolled adults with ankylosing spondylitis (AS) who had an inadequate response (IR) to biologic disease-modifying antirheumatic drug (bDMARD) therapy. Study 2 enrolled adults with non-radiographic axSpA (nr-axSpA). Each study includes a double-blind treatment period and an ongoing open-label extension period. RW period entry was optional.

Double Blind (DB): Week 1 - 14 or 52
Participant flow — Double Blind (DB): Week 1 - 14 or 52
MilestoneDB Study 1: PlaceboDB Study 1: Upadacitinib 15 mgDB Study 2: PlaceboDB Study 2: Upadacitinib 15 mgOL Study 1: Upadacitinib 15 mgOL Study 2: Upadacitinib 15 mgRW Study 1: Off Upadacitinib - No FlareRW Study 2: Off Upadacitinib - No FlareRW Study 1: Upadacitinib 15 mg - No FlareRW Study 2: Upadacitinib 15 mg - No FlareRW Study 1: Upadacitinib 15 mg - FlareRW Study 2: Upadacitinib 15 mg - FlareRW Study 1: Upadacitinib 15 mg - ExtensionRW Study 2: Upadacitinib 15 mg - Extension
Started2092111581560000000000
Received study drug2092111571560000000000
Completed2042061381330000000000
Not completed5520230000000000
Withdrew: Adverse event10130000000000
Withdrew: Withdrawal by subject201280000000000
Withdrew: Lost to follow-up11020000000000
Withdrew: Covid-19 logistical restrictions01000000000000
Withdrew: Other137100000000000
Open Label (OL): Week 14 or 52 - 104
Participant flow — Open Label (OL): Week 14 or 52 - 104
MilestoneDB Study 1: PlaceboDB Study 1: Upadacitinib 15 mgDB Study 2: PlaceboDB Study 2: Upadacitinib 15 mgOL Study 1: Upadacitinib 15 mgOL Study 2: Upadacitinib 15 mgRW Study 1: Off Upadacitinib - No FlareRW Study 2: Off Upadacitinib - No FlareRW Study 1: Upadacitinib 15 mg - No FlareRW Study 2: Upadacitinib 15 mg - No FlareRW Study 1: Upadacitinib 15 mg - FlareRW Study 2: Upadacitinib 15 mg - FlareRW Study 1: Upadacitinib 15 mg - ExtensionRW Study 2: Upadacitinib 15 mg - Extension
Started000041027100000000
Completed000034923900000000
Not completed0000613200000000
Withdrew: Adverse event00005700000000
Withdrew: Withdrawal by subject000023800000000
Withdrew: Lost to follow-up00007400000000
Withdrew: Covid-19 infection00000100000000
Withdrew: Covid-19 logistical restrictions00001000000000
Withdrew: Other0000201100000000
Withdrew: Geo-political restrictions00004100000000
Withdrew: Missing00001000000000
Remission Withdrawal(RW): Week 104 - 235
Participant flow — Remission Withdrawal(RW): Week 104 - 235
MilestoneDB Study 1: PlaceboDB Study 1: Upadacitinib 15 mgDB Study 2: PlaceboDB Study 2: Upadacitinib 15 mgOL Study 1: Upadacitinib 15 mgOL Study 2: Upadacitinib 15 mgRW Study 1: Off Upadacitinib - No FlareRW Study 2: Off Upadacitinib - No FlareRW Study 1: Upadacitinib 15 mg - No FlareRW Study 2: Upadacitinib 15 mg - No FlareRW Study 1: Upadacitinib 15 mg - FlareRW Study 2: Upadacitinib 15 mg - FlareRW Study 1: Upadacitinib 15 mg - ExtensionRW Study 2: Upadacitinib 15 mg - Extension
Started00000018233593526661
Completed00000015193591506458
Not completed00000034002223
Withdrew: Adverse event00000000000022
Withdrew: Withdrawal by subject00000013000101
Withdrew: Lost to follow-up00000000001100
Withdrew: Other00000021001000

Outcome measures

PrimaryStudy 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14

ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 1418.2 (13.0 to 23.4)44.5 (37.8 to 51.3)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 26.4 · 95% CI 17.9 to 34.9Response Rate Difference = Upadacitinib - Placebo
PrimaryStudy 2: Percentage of Participants Achieving an ASAS40 Response at Week 14

ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 1422.5 (16.0 to 29.1)44.9 (37.1 to 52.7)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 22.2 · 95% CI 12.1 to 32.3Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 2.8 · 95% CI 1.7 to 4.5Upadacitinib : Placebo
SecondaryStudy 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14-0.49 (-0.62 to -0.37)-1.52 (-1.64 to -1.39)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Least squares (ls) mean difference: -1.02 · 95% CI -1.20 to -0.85Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14

In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14-0.04 (-1.14 to 1.06)-3.95 (-5.06 to -2.83)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · ANCOVA · p = <0.0001 · Ls mean difference: -3.90 · 95% CI -5.47 to -2.33Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14

The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 1416.7 (11.7 to 21.8)43.1 (36.4 to 49.8)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 26.4 · 95% CI 18.0 to 34.8Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 1: Percentage of Participants With an ASAS20 Response at Week 14

ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants With an ASAS20 Response at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants With an ASAS20 Response at Week 1438.3 (31.7 to 44.9)65.4 (59.0 to 71.8)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 27.1 · 95% CI 17.9 to 36.3Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 1: Percentage of Participants With ASDAS Inactive Disease at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 141.9 (0.1 to 3.8)12.8 (8.3 to 17.3)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 10.9 · 95% CI 6.0 to 15.8Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14-1.47 (-1.77 to -1.16)-3.00 (-3.30 to -2.70)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.53 · 95% CI -1.96 to -1.11Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14-1.52 (-1.84 to -1.20)-3.21 (-3.52 to -2.89)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.69 · 95% CI -2.14 to -1.24Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 1410.1 (6.0 to 14.2)44.1 (37.4 to 50.8)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 34.0 · 95% CI 26.2 to 41.8Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14

The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14-1.09 (-1.35 to -0.83)-2.26 (-2.53 to -2.00)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.17 · 95% CI -1.55 to -0.80Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Percentage of Participants With ASAS Partial Remission at Week 14

ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 1: Percentage of Participants With ASAS Partial Remission at Week 14
percentage of participantsStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Percentage of Participants With ASAS Partial Remission at Week 144.3 (1.6 to 7.1)17.5 (12.4 to 22.7)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 13.2 · 95% CI 7.4 to 19.0Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14

The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14-2.03 (-2.62 to -1.44)-5.10 (-5.69 to -4.52)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -3.07 · 95% CI -3.90 to -2.24Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in ASAS Health Index at Week 14

The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in ASAS Health Index at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in ASAS Health Index at Week 14-1.07 (-1.51 to -0.64)-2.93 (-3.36 to -2.50)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.85 · 95% CI -2.47 to -1.24Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14

The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14-0.16 (-0.26 to -0.06)-0.48 (-0.58 to -0.38)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.32 · 95% CI -0.46 to -0.18Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14

The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14-1.1 (-1.5 to -0.8)-2.6 (-3.0 to -2.2)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.5 · 95% CI -2.0 to -0.9Treatment difference = Upadacitinib - Placebo
SecondaryStudy 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14

In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14
score on a scaleStudy 1: PlaceboStudy 1: Upadacitinib 15 mg
Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 141.05 (0.22 to 1.89)-2.26 (-3.10 to -1.41)
Statistical analysis
  • Study 1: Placebo vs Study 1: Upadacitinib 15 mg · ANCOVA · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Ls mean difference: -3.31 · 95% CI -4.50 to -2.12Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in ASDAS at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in ASDAS at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in ASDAS at Week 14-0.71 (-0.85 to -0.56)-1.36 (-1.50 to -1.21)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -0.65 · 95% CI -0.85 to -0.45Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14

In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 140.57 (-0.17 to 1.30)-2.49 (-3.22 to -1.77)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · ANCOVA · p = <0.0001 · Ls mean difference: -3.06 · 95% CI -4.08 to -2.04Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants With BASDAI 50 Response at Week 14

The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With BASDAI 50 Response at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With BASDAI 50 Response at Week 1422.1 (15.5 to 28.6)42.3 (34.6 to 50.1)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0001 · Response rate difference: 20.1 · 95% CI 10.1 to 30.1Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 2.6 · 95% CI 1.6 to 4.2Upadacitinib : Placebo
SecondaryStudy 2: Percentage of Participants With ASDAS Inactive Disease at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 145.2 (1.7 to 8.7)14.1 (8.6 to 19.6)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0063 · Response rate difference: 8.8 · 95% CI 2.5 to 15.2Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 3.0 · 95% CI 1.3 to 7.0Upadacitinib : Placebo
SecondaryStudy 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14

Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14-2.00 (-2.35 to -1.65)-2.91 (-3.27 to -2.56)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = 0.0004 · Ls mean difference: -0.92 · 95% CI -1.42 to -0.41Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14

Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14-1.84 (-2.23 to -1.44)-2.96 (-3.36 to -2.56)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = 0.0001 · Ls mean difference: -1.12 · 95% CI -1.68 to -0.55Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 1418.3 (12.2 to 24.4)42.3 (34.6 to 50.1)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 23.8 · 95% CI 14.2 to 33.4Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 3.2 · 95% CI 1.9 to 5.4Upadacitinib : Placebo
SecondaryStudy 2: Percentage of Participants With ASAS Partial Remission at Week 14

ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASAS Partial Remission at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASAS Partial Remission at Week 147.6 (3.5 to 11.8)18.6 (12.5 to 24.7)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0035 · Response rate difference: 10.9 · 95% CI 3.6 to 18.3Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 2.7 · 95% CI 1.3 to 5.6Upadacitinib : Placebo
SecondaryStudy 2: Change From Baseline in BASFI at Week 14

The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in BASFI at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in BASFI at Week 14-1.47 (-1.79 to -1.15)-2.61 (-2.94 to -2.29)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.14 · 95% CI -1.60 to -0.68Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in ASQoL at Week 14

The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in ASQoL at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in ASQoL at Week 14-3.15 (-3.87 to -2.43)-5.38 (-6.11 to -4.65)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -2.23 · 95% CI -3.26 to -1.21Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in ASAS Health Index at Week 14

The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in ASAS Health Index at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in ASAS Health Index at Week 14-1.48 (-2.02 to -0.93)-3.26 (-3.81 to -2.70)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -1.78 · 95% CI -2.56 to -1.00Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants Achieving an ASAS20 Response at Week 14

ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 1443.8 (36.0 to 51.5)66.7 (59.3 to 74.1)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 22.8 · 95% CI 12.2 to 33.4Response Rate Difference = Upadacitinib - Placebo
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Odds ratio (or): 2.5 · 95% CI 1.6 to 4.0Upadacitinib : Placebo
SecondaryStudy 2: Change From Baseline in BASMI(Lin) at Week 14

The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in BASMI(Lin) at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in BASMI(Lin) at Week 14-0.19 (-0.29 to -0.08)-0.29 (-0.40 to -0.18)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · ANCOVA · p = 0.1781 · Ls mean difference: -0.10 · 95% CI -0.25 to 0.05Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in MASES at Week 14

The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in MASES at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in MASES at Week 14-1.6 (-2.0 to -1.2)-2.3 (-2.7 to -1.9)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Mixed-effect Model Repeated Measurement · p = 0.0193 · Ls mean difference: -0.7 · 95% CI -1.3 to -0.1Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants Achieving an ASAS40 Response at Week 52

ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 5242.7 (34.9 to 50.4)62.8 (55.2 to 70.4)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0003 · Response rate difference: 20.1 · 95% CI 9.3 to 30.9Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14

In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · score on a scale
Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14
score on a scaleStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 140.34 (-0.32 to 1.00)-0.79 (-1.48 to -0.11)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · ANCOVA · p = 0.0206 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Ls mean difference: -1.13 · 95% CI -2.08 to -0.17Treatment difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52

Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.

Time frame:
Week 24, Week 32, Week 40, and Week 52
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Week 2413.4 (8.5 to 19.7)5.1 (2.2 to 9.9)
Week 321.9 (0.4 to 5.5)3.2 (1.0 to 7.3)
Week 400.6 (0.0 to 3.5)0.6 (0.0 to 3.5)
Week 521.3 (0.2 to 4.5)0 (0.0 to 2.3)
SecondaryStudy 2: Percentage of Participants With ASDAS Major Improvement at Week 52

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASDAS Major Improvement at Week 5220.4 (14.1 to 26.7)37.8 (30.2 to 45.4)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0004 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 17.6 · 95% CI 7.9 to 27.3Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants With ASDAS Inactive Disease at Week 52

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 5210.8 (6.0 to 15.7)32.7 (25.3 to 40.1)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 21.9 · 95% CI 13.2 to 30.6Response Rate Difference = Upadacitinib - Placebo
SecondaryStudy 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52

ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52
percentage of participantsStudy 2: PlaceboStudy 2: Upadacitinib 15 mg
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 5232.5 (25.2 to 39.9)55.8 (48.0 to 63.6)
Statistical analysis
  • Study 2: Placebo vs Study 2: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 23.1 · 95% CI 12.4 to 33.7Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection/time of informed consent/enrollment (all are acceptable; whichever study team prefers per protocol/study design) to the end of the study. The median time on follow-up (or mean time participants were followed) was 769.5, 902.5, 837.0, 861.0, 794.0, 1015.0, 0.0, 1183.0, 1026.0, 1059.0, 1092.0, 1081.0, 1226.5, and 1182.0 days for arms:. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Study 1: Placebo0/209 (0%)1/209 (0.5%)35/209 (16.7%)
DB Study 1: Upadacitinib 15 mg0/211 (0%)6/211 (2.8%)41/211 (19.4%)
OL Study 1: Upadacitinib 15 mg1/410 (0.2%)44/410 (10.7%)172/410 (42%)
DB Study 2: Placebo0/158 (0%)6/158 (3.8%)69/158 (43.7%)
DB Study 2: Upadacitinib 15 mg0/156 (0%)7/156 (4.5%)67/156 (42.9%)
OL Study 2: Upadacitinib 15 mg0/271 (0%)22/271 (8.1%)107/271 (39.5%)
RW Study 1: Upadacitinib 15 mg - No Flare0/3 (0%)0/3 (0%)2/3 (66.7%)
RW Study 2: Upadacitinib 15 mg - No Flare0/5 (0%)1/5 (20%)4/5 (80%)
RW Study 1: Upadacitinib 15 mg - Flare0/93 (0%)2/93 (2.2%)28/93 (30.1%)
RW Study 2: Upadacitinib 15 mg - Flare0/52 (0%)3/52 (5.8%)19/52 (36.5%)
RW Study 1: Off Upadacitinib - No Flare0/18 (0%)0/18 (0%)4/18 (22.2%)
RW Study 2: Off Upadacitinib - No Flare0/23 (0%)2/23 (8.7%)6/23 (26.1%)
RW Study 1: Upadacitinib 15 mg - Extension0/66 (0%)2/66 (3%)20/66 (30.3%)
RW Study 2: Upadacitinib 15 mg - Extension0/61 (0%)2/61 (3.3%)22/61 (36.1%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventDB Study 1: PlaceboDB Study 1: Upadacitinib 15 mgOL Study 1: Upadacitinib 15 mgDB Study 2: PlaceboDB Study 2: Upadacitinib 15 mgOL Study 2: Upadacitinib 15 mgRW Study 1: Upadacitinib 15 mg - No FlareRW Study 2: Upadacitinib 15 mg - No FlareRW Study 1: Upadacitinib 15 mg - FlareRW Study 2: Upadacitinib 15 mg - FlareRW Study 1: Off Upadacitinib - No FlareRW Study 2: Off Upadacitinib - No FlareRW Study 1: Upadacitinib 15 mg - ExtensionRW Study 2: Upadacitinib 15 mg - Extension
HYPERTENSIONVascular disorders0/2090/2110/4100/1580/1561/2710/31/50/930/520/180/230/660/61
PNEUMONIA VIRALInfections and infestations0/2090/2110/4100/1580/1560/2710/30/50/930/520/181/230/660/61
SEIZURENervous system disorders0/2090/2110/4100/1580/1560/2710/30/50/930/520/181/230/660/61
LATENT SYPHILISInfections and infestations0/2090/2110/4100/1580/1560/2710/30/50/931/520/180/230/660/61
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders0/2090/2110/4100/1580/1560/2710/30/50/931/520/180/230/660/61
CERVICAL DYSPLASIAReproductive system and breast disorders0/2090/2110/4100/1580/1560/2710/30/50/931/520/180/230/660/61
HEAVY MENSTRUAL BLEEDINGReproductive system and breast disorders0/2090/2110/4100/1580/1561/2710/30/50/931/520/180/230/660/61
COVID-19 PNEUMONIAInfections and infestations0/2094/2117/4100/1581/1562/2710/30/50/930/520/180/230/660/61
PNEUMONIAInfections and infestations0/2090/2111/4100/1580/1560/2710/30/50/930/520/180/230/661/61
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2090/2111/4100/1580/1560/2710/30/51/930/520/180/230/661/61
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDB Study 1: PlaceboDB Study 1: Upadacitinib 15 mgOL Study 1: Upadacitinib 15 mgDB Study 2: PlaceboDB Study 2: Upadacitinib 15 mgOL Study 2: Upadacitinib 15 mgRW Study 1: Upadacitinib 15 mg - No FlareRW Study 2: Upadacitinib 15 mg - No FlareRW Study 1: Upadacitinib 15 mg - FlareRW Study 2: Upadacitinib 15 mg - FlareRW Study 1: Off Upadacitinib - No FlareRW Study 2: Off Upadacitinib - No FlareRW Study 1: Upadacitinib 15 mg - ExtensionRW Study 2: Upadacitinib 15 mg - Extension
COVID-19Infections and infestations5/20910/21178/41022/15820/15659/2710/32/55/934/520/181/236/663/61
ILEAL ULCERGastrointestinal disorders0/2090/2110/4100/1580/1560/2711/30/50/930/520/180/231/660/61
NASOPHARYNGITISInfections and infestations3/2095/21128/4108/15812/15616/2711/31/58/934/520/182/234/662/61
LIMB INJURYInjury, poisoning and procedural complications0/2090/2111/4100/1581/1560/2711/30/50/930/520/180/230/660/61
PLATELET COUNT DECREASEDInvestigations0/2090/2110/4100/1580/1560/2711/30/50/930/520/180/230/660/61
WEIGHT INCREASEDInvestigations0/2091/2111/4100/1585/1564/2711/30/50/930/520/180/230/660/61
ECZEMASkin and subcutaneous tissue disorders0/2090/2110/4102/1580/1561/2711/30/50/930/520/180/230/661/61
ARTERIOSCLEROSIS CORONARY ARTERYCardiac disorders0/2090/2110/4100/1580/1560/2710/31/50/930/520/180/230/660/61
CHEST DISCOMFORTGeneral disorders0/2090/2111/4100/1580/1560/2710/31/50/930/520/180/230/660/61
POST-ACUTE COVID-19 SYNDROMEInfections and infestations0/2090/2111/4100/1582/1560/2710/31/50/930/520/180/230/660/61

Baseline characteristics

The full analysis set (FAS) includes all randomized participants who received at least one dose of study drug (upadacitinib or placebo).

Age, Continuous
Age, Continuous(years)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 142.2 ± 11.7842.6 ± 12.39——42.4 ± 12.08
Study 2——42.5 ± 12.4441.6 ± 12.0042.1 ± 12.21
Age, Customized
Age, Customized(Participants)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 — < 40 years9287——179
Study 1 — 40 - < 65 years108112——220
Study 1 — ≥ 65 years912——21
Study 2 — < 40 years——6772139
Study 2 — 40 - < 65 years——8481165
Study 2 — ≥ 65 years——639
Sex: Female, Male
Sex: Female, Male(Participants)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 — Female5158——109
Study 1 — Male158153——311
Study 2 — Female——9489183
Study 2 — Male——6367130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 — Hispanic or Latino2017——37
Study 1 — Not Hispanic or Latino189194——383
Study 1 — Unknown or Not Reported00——0
Study 2 — Hispanic or Latino——152439
Study 2 — Not Hispanic or Latino——142132274
Study 2 — Unknown or Not Reported——000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 — American Indian or Alaska Native00——0
Study 1 — Asian3742——79
Study 1 — Native Hawaiian or Other Pacific Islander00——0
Study 1 — Black or African American31——4
Study 1 — White169168——337
Study 1 — More than one race00——0
Study 1 — Unknown or Not Reported00——0
Study 2 — American Indian or Alaska Native——011
Study 2 — Asian——281947
Study 2 — Native Hawaiian or Other Pacific Islander——000
Study 2 — Black or African American——123
Study 2 — White——127134261
Study 2 — More than one race——101
Study 2 — Unknown or Not Reported——000
Region
Region(Participants)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 — North America2525——50
Study 1 — South/Central America1413——27
Study 1 — Western Europe2516——41
Study 1 — Eastern Europe98109——207
Study 1 — Asia3441——75
Study 1 — Other137——20
Study 2 — North America——192645
Study 2 — South/Central America——131225
Study 2 — Western Europe——192443
Study 2 — Eastern Europe——7268140
Study 2 — Asia——271946
Study 2 — Other——7714
Time Since AS / nr-axSpA Diagnosis
Time Since AS / nr-axSpA Diagnosis(years)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 - Duration since AS diagnosis7.5 ± 7.517.9 ± 7.54——7.7 ± 7.52
Study 2 - Duration since nr-axSpA diagnosis——4.4 ± 5.834.5 ± 5.544.4 ± 5.68
Duration of AS / nr-axSpA Symptoms
Duration of AS / nr-axSpA Symptoms(years)Study 1: PlaceboStudy 1: Upadacitinib 15 mgStudy 2: PlaceboStudy 2: Upadacitinib 15 mgTotal
Study 1 -Duration of AS symptoms12.6 ± 9.2912.9 ± 9.08——12.8 ± 9.18
Study 2 - Duration of nr-axSpA symptoms——9.2 ± 8.129.0 ± 7.869.1 ± 7.98

11 further baseline measures are reported on the registry.

09

Study locations

212 sites
  • Arizona Arthritis & Rheumatology Associates, P.C. /ID# 215282
    Flagstaff, Arizona 86001-6269, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 215113
    Phoenix, Arizona 85032-9306, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 214731
    Tucson, Arizona 85704, United States
  • Newport Huntington Medical Group /ID# 216281
    Huntington Beach, California 92648-5994, United States
  • Inland Rheum & Osteo Med Grp /ID# 215807
    Upland, California 91786, United States
  • Denver Arthritis Clinic /ID# 215346
    Denver, Colorado 80230, United States
  • Tekton Research /ID# 215054
    Fort Collins, Colorado 80528, United States
  • Arthritis & Rheumatic Disease Specialties /ID# 215306
    Aventura, Florida 33180, United States
  • Sweet Hope Research Specialty Inc /ID# 215931
    Hialeah, Florida 33016-1897, United States
  • Innovation Medical Research Center /ID# 216068
    Palmetto Bay, Florida 33157-1737, United States
  • Conquest Research /ID# 215804
    Winter Park, Florida 32789, United States
  • Great Lakes Clinical Trials /ID# 215790
    Chicago, Illinois 60640, United States
  • Greater Chicago Specialty Physicians /ID# 216213
    Schaumburg, Illinois 60195-3106, United States
  • Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055
    Skokie, Illinois 60076, United States
  • Klein and Associates MD /ID# 214767
    Hagerstown, Maryland 21740, United States
  • Tufts Medical Center /ID# 215925
    Boston, Massachusetts 02111-1552, United States
  • Clinical Pharmacology Study Group /ID# 215293
    Worcester, Massachusetts 01605, United States
  • Wayne State University Health Center /ID# 215930
    Detroit, Michigan 48201-2153, United States
  • Advanced Rheumatology, PC /ID# 214973
    Lansing, Michigan 48910, United States
  • St. Paul Rheumatology /ID# 215537
    Eagan, Minnesota 55121, United States
  • Clinvest Research LLC /ID# 215785
    Springfield, Missouri 65807, United States
  • CenterPointe Institute of Research /ID# 215793
    St Louis, Missouri 63128-3841, United States
  • NYU Langone Orthopedic Center /ID# 215594
    New York, New York 10016-2772, United States
  • St. Lawrence Health System /ID# 215844
    Potsdam, New York 13676, United States
  • Cape Fear Arthritis Care /ID# 215927
    Leland, North Carolina 28451, United States
  • Marietta Memorial Hospital /ID# 215929
    Marietta, Ohio 45750-1635, United States
  • STAT Research, Inc. /ID# 215264
    Springboro, Ohio 45066, United States
  • Health Research of Oklahoma /ID# 215117
    Oklahoma City, Oklahoma 73103-2400, United States
  • Oregon Health and Science University /ID# 216446
    Portland, Oregon 97239, United States
  • Altoona Ctr Clinical Res /ID# 214770
    Duncansville, Pennsylvania 16635, United States
  • Tekton Research, Inc. /ID# 214923
    Austin, Texas 78745, United States
  • Trinity Universal Research Associates - Carrollton /ID# 214948
    Carrollton, Texas 75007, United States
  • Arthritis and Osteoporosis Clinic Of Brazos Valley /ID# 215805
    College Station, Texas 77845, United States
  • JPS Rheumatology Clinic /ID# 215962
    Fort Worth, Texas 76104-4917, United States
  • Memorial Rheumatology /ID# 216311
    Houston, Texas 77024-2420, United States
  • Biopharma Informatic, LLC /ID# 215885
    Houston, Texas 77043, United States
  • Biopharma Informatic - Park Row /ID# 215907
    Houston, Texas 77084, United States
  • West Texas Clinical Research /ID# 215928
    Lubbock, Texas 79410-1198, United States
  • Trinity Universal Research Associates, Inc /ID# 215189
    Plano, Texas 75024-5283, United States
  • Rheumatology and Pulmonary Clinic /ID# 214946
    Beckley, West Virginia 25801, United States
  • West Virginia Research Inst /ID# 214921
    South Charleston, West Virginia 25309, United States
  • Organizacion Medica de Investigacion (OMI) /ID# 214557
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires 1015, Argentina
  • Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 214556
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto CAICI /ID# 215242
    Rosario, Santa Fe Province 2000, Argentina
  • Centro de Investigaciones Medicas Tucuman /ID# 214559
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Hospital Cordoba /ID# 215846
    Córdoba, 5000, Argentina
  • Instituto Medico Strusberg /ID# 215239
    Córdoba, 5000, Argentina
  • Cimer /Id# 215240
    San Miguel de Tucumán, 4000, Argentina
  • Emeritus Research Sydney /ID# 215507
    Botany, New South Wales 2019, Australia
  • BJC Health /ID# 215510
    Parramatta, New South Wales 2150, Australia
  • Emeritus Research /ID# 215506
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre /ID# 215509
    Clayton, Victoria 3168, Australia
  • Barwon Rheumatology Services /ID# 215508
    Geelong, Victoria 3220, Australia
  • UZ Gent /ID# 215004
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Leuven /ID# 215006
    Leuven, Vlaams-Brabant 3000, Belgium
  • ReumaClinic /ID# 215005
    Genk, 3600, Belgium
  • CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 215277
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • EDUMED Educacao em Saude S/S L /ID# 215111
    Curitiba, Paraná 80440-080, Brazil
  • LMK Sevicos Medicos S/S /ID# 215112
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 215176
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas /ID# 215175
    São Paulo, 01228-200, Brazil
  • UMHAT Kaspela EOOD /ID# 214803
    Plovdiv, 4001, Bulgaria
  • Medical center Unimed /ID# 214816
    Plovdiv, 4023, Bulgaria
  • MHAT Plovdiv /ID# 214815
    Plovdiv, 4027, Bulgaria
  • Medical center Teodora /ID# 214813
    Rousse, 7012, Bulgaria
  • Medical center Excelsior /ID# 214805
    Sofia, 1407, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 214804
    Sofia, 1431, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 214806
    Sofia, 1431, Bulgaria
  • Diagnostic consultative center 17 Sofia /ID# 214808
    Sofia, 1505, Bulgaria
  • Percuro Clinical Research, Ltd /ID# 215302
    Victoria, British Columbia V8V 3M9, Canada
  • Toronto Western Hospital /ID# 215041
    Toronto, Ontario M5T 2S8, Canada
  • Applied Medical Informatics Research Inc. (AMIR) /ID# 215303
    Montreal, Quebec H4A 3T2, Canada
  • Centre de Recherche Musculo-Squelettique /ID# 215096
    Trois-Rivières, Quebec G8Z 1Y2, Canada
  • Centre de recherche du CHUQ /ID# 215038
    Québec, G1R 3S2, Canada
  • The first affiliated hospital of bengbu medical college /ID# 216609
    Bengbu, Anhui 233004, China
  • Anhui Provincial Hospital /ID# 216631
    Hefei, Anhui 230001, China
  • Peking Union Medical College Hospital /ID# 216545
    Beijing, Beijing Municipality 100730, China
  • Guangdong Provincial People's Hospital /ID# 216645
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Shantou University Medical College /ID# 217883
    Shantou, Guangdong 515041, China
  • Shenzhen People's Hospital /ID# 225438
    Shenzhen, Guangdong 518020, China
  • Zhuzhou Central Hospital /ID# 216644
    Zhuzhou, Hunan 412007, China
  • The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia Universi /ID# 216612
    Baotou, Inner Mongolia 014016, China
  • The First Affiliated Hospital of Soochow University /ID# 216607
    Suzhou, Jiangsu 215006, China
  • Huashan Hospital, Fudan University /ID# 216646
    Shanghai, Shanghai Municipality 200040, China
  • First Affiliated Hospital of Kunming Medical University /ID# 217945
    Kunming, 650032, China
  • REVMACLINIC s.r.o. /ID# 215153
    Brno, 602 00, Czechia
  • Revmacentrum MUDr. Mostera, s.r.o. /ID# 215161
    Brno, 615 00, Czechia
  • Revmatologie, s.r.o. /ID# 215309
    Brno, 638 00, Czechia
  • CCR Ostrava, s.r.o. /ID# 215226
    Ostrava, 702 00, Czechia
  • ARTHROHELP, s.r.o. /ID# 215224
    Pardubice, 530 02, Czechia
  • Revmatologicky ustav v Praze /ID# 215154
    Prague, 128 00, Czechia
  • PV MEDICAL Services s.r.o. /ID# 215119
    Prague, 130 00, Czechia
  • Revmatologicka ambulance - MUDr. Zuzana Urbanova /ID# 215652
    Prague, 140 00, Czechia
  • Thomayerova nemocnice /ID# 215118
    Prague, 140 59, Czechia
  • Fakultni Nemocnice v Motole /ID# 215160
    Prague, 150 06, Czechia
  • MEDICAL PLUS, s.r.o. /ID# 215324
    Uherské Hradiště, 686 01, Czechia
  • CHU Toulouse /ID# 214780
    Toulouse, Occitanie 31300, France
  • CHU Bordeaux - Hopital Pellegrin /ID# 214784
    Bordeaux, 33000, France
  • Hopital Ambroise Pare /ID# 214783
    Boulogne-Billancourt, 92104, France
  • AP-HP - Hopital Cochin /ID# 214782
    Paris, 75014, France

Showing the first 100 of 212 sites across 25 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13. PubMed 41824252 ↗
  • Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2. PubMed 41039829 ↗
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110. PubMed 40037923 ↗
  • Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Res Ther. 2025 Feb 4;27(1):23. doi: 10.1186/s13075-024-03441-3. PubMed 39905436 ↗
  • Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024 Nov 12;26(1):197. doi: 10.1186/s13075-024-03412-8. PubMed 39533349 ↗
  • Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29. PubMed 38683479 ↗
  • Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20. PubMed 37982966 ↗
  • Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D. Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther. 2023 Aug;10(4):887-899. doi: 10.1007/s40744-023-00550-4. Epub 2023 May 16. PubMed 37191738 ↗
  • Navarro-Compan V, Baraliakos X, Magrey M, Ostor A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis. Rheumatol Ther. 2023 Jun;10(3):679-691. doi: 10.1007/s40744-023-00536-2. Epub 2023 Feb 23. PubMed 36820984 ↗
  • Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0. PubMed 35908570 ↗
  • van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. PubMed 35788492 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Sep 2021, 21 months.

Results were first posted in Sep 2022, 1 year after primary completion.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 19, 2019
StartActual
Nov 26, 2019
Primary completionActual
Sep 2, 2021
CompletionActual
Feb 28, 2025
Results first posted
Sep 21, 2022
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04169373
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Nov 26, 2019
Primary completion
Sep 2, 2021
Completion
Feb 28, 2025
Results posted
Sep 21, 2022
Last update
Feb 24, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion